Breast Cancer (Therapy)

More on Tamoxifen and Raloxifene: U.S. Government Weighs Benefits, Risks

Published in Women's Health Weekly, May 4th, 1998

Amid optimistic reports that two drugs might help prevent breast cancer, the U.S. government is struggling to help women decide who should start using the pills or if the side effects are too risky.

For one of the drugs, the government had a stark message April 22, 1998: Despite headlines trumpeting raloxifene, Eli Lilly's new osteoporosis drug, there is no good evidence yet that the medicine truly wards off breast cancer.

But a National Cancer Institute (NCI) study did find that a related medicine, tamoxifen, cuts the chances of breast cancer by a significant 45 percent in certain women, and the NCI said it is preparing kits to help doctors target...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1998-05-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry